Thanks, LED. But just pointing out that someone already noticed a difference in language between the last 2 applications...
https://hotcopper.com.au/threads/ann-fda-accepts-mesoblasts-bla-resubmission-for-remestemcel-l.8110020/page-62?post_id=74876192
Just thinking if management had gone for a smaller target after their CRLs but were encouraged enough after the FDA feedback recently to go back to full U18 approval which I am pretty sure was in their initial ODAC application.
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-108
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
-0.030(2.29%) |
Mkt cap ! $1.461B | |||
| Open | High | Low | Value | Volume |
| $1.32 | $1.35 | $1.28 | $1.677M | 1.289M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 44452 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 23596 | 1 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |